bepridil has been researched along with nutlin-3a in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dawoodian, A; Li, E; Momand, J; Sanchez, R; Warner, WA | 1 |
| Darabedian, N; Enriquez, E; Magdziarz, P; Momand, J; Quan, C; Wang, X; Zhao, W; Zhou, F | 1 |
2 other study(ies) available for bepridil and nutlin-3a
| Article | Year |
|---|---|
Identification of FDA-approved drugs that computationally bind to MDM2.
Topics: Bepridil; Computer-Aided Design; Drug Approval; Drug Design; Humans; Imidazoles; Molecular Conformation; Molecular Docking Simulation; Piperazines; Proto-Oncogene Proteins c-mdm2; United States; United States Food and Drug Administration | 2012 |
Surface plasmon resonance and cytotoxicity assays of drug efficacies predicted computationally to inhibit p53/MDM2 interaction.
Topics: Bepridil; Cell Line, Tumor; Humans; Imidazoles; Piperazines; Protein Binding; Proto-Oncogene Proteins c-mdm2; Small Molecule Libraries; Surface Plasmon Resonance; Tumor Suppressor Protein p53 | 2019 |